TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06243835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kindolor Tosylate
Description: Kindolor Tosylate enteric coated tablets containing the specified amount of drug product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kindolor Tosylate
Description: Kindolor Tosylate enteric coated tablets containing the specified amount of drug product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kindolor Tosylate
Description: Kindolor Tosylate enteric coated tablets containing the specified amount of drug product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kindolor Tosylate
Description: Kindolor Tosylate enteric coated tablets containing the specified amount of drug product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo enteric coated tablets identically matched to the Kindolor Tosylate tablets with equal amount of Prosolv SMCC replacing the Kindolor Tosylate
Study: NCT06202521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945 (SARS-CoV-2 domain)
Description: CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (SARS-CoV-2 domain)
Description: The dosage and frequency is the same as active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945 (Influenza virus domain)
Description: CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Influenza virus domain)
Description: The dosage and frequency is the same as active drug.
Study: NCT05083780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorphenesin Carbamate, Hydroxychloroquine
Description: In addition to the mFOLFIRINOX therapy(backbone therapy), chlorphenesin carbamate 250 mg, and hydroxychloroquine 200 mg will be administered orally twice daily for up to 48 weeks.
Study: NCT05263492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib once a day by mouth every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.
Study: NCT06216886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 UNT [Botox]
Description: Intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of onabotA. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% for Injection, Preservative Free
Description: intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of saline. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
Study: NCT06318520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Calcium silicate based resin cement and resin modified glass ionomer cement
Description: Investigators will restore MIH teeth with stainless steel crowns using calcium silicate-based resin cement and resin-modified glass ionomer cement and evaluate their 1-year success.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Calcium silicate based resin cement and resin modified glass ionomer cement
Description: Investigators will restore MIH teeth with stainless steel crowns using calcium silicate-based resin cement and resin-modified glass ionomer cement and evaluate their 1-year success.
Study: NCT05452460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: The mindfulness program called Mindfulness-based peak performance (MBPP) will be used in this study. MBPP is a program that consists of eight 60-min training, and a 60-min session weekly for 8-weeks. The MBPP program will include (1) 5 minutes of will start with a brief recap of the preceding session and homework discussion, (2) after which the 5 minutes of a brief story about performance aimed at inducing the learning motivation of the participants; (3) Followed by 20 minutes of a theoretical lecture introducing a new topic and then (4) 25 minutes of mindfulness exercise. (5) Finally, how to apply the mindfulness skills to sports context will be discussed at the end of each session for 5 minutes.
Study: NCT04665739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given FDG

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Given FDG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT05127473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 100 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 100 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
Study: NCT06232603

Intervention type: OTHER
Group type: OTHER
Intervention: Education of medication management
Description: Video and handout materials will be provided
Study: NCT06557057

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT05587231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: The experimental group will have the Dextenza Insert implanted immediately after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Fluorometholone
Description: Steroid drops will be administered by the subject according to the standard of care taper
Study: NCT04665739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT
Study: NCT04945707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]
Description: Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject \<50 kg, 20 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT05577598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of a DBS therapy system
Description: The system is called Reclaim DBS Therapy for OCD und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula.
Study: NCT04665739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05577598

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Implantation of a DBS therapy system
Description: The system is called Reclaim DBS Therapy for OCD und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula.
Study: NCT05952765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant
Description: * Local anesthesia Septanest special® will be administered prior to the procedure.~* Teeth extraction will be initiated by intrasulcular incision via 15 C blade without flap elevation.~* The tooth to be extracted will be luxated atraumatically using periotomes and thin straight elevator and delivered using forceps.~* The socket will be inspected for integrity, using a UNC graduated periodontal probe.~grafting material either experimental or control will be used to graft jumping gap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant
Description: * Local anesthesia Septanest special® will be administered prior to the procedure.~* Teeth extraction will be initiated by intrasulcular incision via 15 C blade without flap elevation.~* The tooth to be extracted will be luxated atraumatically using periotomes and thin straight elevator and delivered using forceps.~* The socket will be inspected for integrity, using a UNC graduated periodontal probe.~grafting material either experimental or control will be used to graft jumping gap.
Study: NCT05127473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 100 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 100 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, placebo
Description: Placebo will be used to dilute the IMP to different Mim8 concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, placebo
Description: Placebo will be used to dilute the IMP to different Mim8 concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, placebo
Description: Placebo will be used to dilute the IMP to different Mim8 concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, placebo
Description: Placebo will be used to dilute the IMP to different Mim8 concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, placebo
Description: Placebo will be used to dilute the IMP to different Mim8 concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, placebo
Description: Placebo will be used to dilute the IMP to different Mim8 concentrations
Study: NCT06269744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Screening Outreach
Description: Individuals in the interventional arm will receive an information letter, followed by mailed FIT kit. Individuals that do not respond will receive reminder phone calls. Individuals that do respond will receive navigation to assist with completion of FIT and the colonoscopy if FIT is abnormal. Clinic processes will be closely followed and the primary care provider will be informed of the program.
Study: NCT05864638

Intervention type: DEVICE
Intervention: Endovascular treatment
Description: Endovascular treatment, such as mechanical thrombectomy with stent, aspiration catheter or stent assisted by intermediate aspiration catheter, as well as combination of mechanical thrombectomy with intra-arterial thrombolysis
Study: NCT06400511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus 0.3% Ophthalmic Ointment
Description: Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Ointment
Description: Placebo will be applied twice a day to both eyelid margins.
Study: NCT06253013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyfe Smartwatch
Description: Passive recording of audio with detection of explosive sounds. When explosive sounds are detected, a 0.5-1 seconds audio clip is recorded, and run through an algorithm to determine whether or not it is a cough.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit Versa 2
Description: Commercial watch with the capability to monitor vital signs including oxygen saturation, respiratory rate and heart rate. Patients will be able to view their data in the FitBit app.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Spirometer
Description: Patients will be able to perform spirometry testing at home. They will be able to view their data, and it will be uploaded to a dashboard for clinicians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio recording
Description: Patients will be asked to record several sentences which will be analyzed to detect speech patterns that may indicate changes in respiratory conditions.
Study: NCT04324619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online interactive learning activities
Description: 1. 3-hour video-storyline-based interactive learning program~2. Micro-learning activities that can be completed on mobile devices (eg, smartphones)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online interactive learning activities
Description: 1. 3-hour video-storyline-based interactive learning program~2. Micro-learning activities that can be completed on mobile devices (eg, smartphones)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online interactive learning activities
Description: 1. 3-hour video-storyline-based interactive learning program~2. Micro-learning activities that can be completed on mobile devices (eg, smartphones)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online interactive learning activities
Description: 1. 3-hour video-storyline-based interactive learning program~2. Micro-learning activities that can be completed on mobile devices (eg, smartphones)
Study: NCT04954573

Intervention type: RADIATION
Group type: OTHER
Intervention: infrared-A (wIRA)
Description: Local-water filtered infrared-A (wIRA) irradiation

Intervention type: RADIATION
Group type: OTHER
Intervention: infrared-A (wIRA)
Description: Local-water filtered infrared-A (wIRA) irradiation
Study: NCT06436625

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: outpatient pulmonary rehabilitation
Description: Patients undergo six weeks of an outpatient rehabilitation program in one of the rehabilitation centers (Therme Wien Med, Klinik Pirawarth in Wien).
Study: NCT05427006

Intervention type: DEVICE
Intervention: Z5-BL Dental Implants
Description: This is an observational study, collecting data on the use of Z5-BL Dental Implants.

Intervention type: DEVICE
Intervention: Z5-TL Dental Implants
Description: This is an observational study, collecting data on the use of Z5-BL Dental Implants.
Study: NCT05856890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepB mAb19
Description: HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepB mAb19
Description: HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepB mAb19
Description: HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepB mAb19
Description: HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepB mAb19
Description: HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Placebo will be normal sterile saline (NaCl 0.9%).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Placebo will be normal sterile saline (NaCl 0.9%).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Placebo will be normal sterile saline (NaCl 0.9%).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Placebo will be normal sterile saline (NaCl 0.9%).
Study: NCT06088290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Intravenous Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Short intravenous push or bolus (according to label)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Short intravenous push or bolus (according to label)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Short intravenous push or bolus (according to label)
Study: NCT05644951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hot AXIOS system used for EPASS
Description: EUS-guided double-balloon-occluded gastrojejunostomy bypass with Hot AXIOS system
Study: NCT05507970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367
Description: Single dose dispersed in sterile water, fasted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367
Description: Single dose dispersed in sterile water, fasted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367
Description: Single dose dispersed in sterile water, fasted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367
Description: Single dose dispersed in sterile water, fasted.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Dose dispersed in sterile water, fasted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367 (Fed 440mg)
Description: Single dose dispersed in sterile water with a high fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367
Description: Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
Study: NCT05264129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablet
Study: NCT05507970

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367 (Fasted 440mg)
Description: Single dose dispersed in sterile water fasted.
Study: NCT04748601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qudexy XR
Description: Extended-Release Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Qudexy XR Matching capsules
Study: NCT06383936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensive rehabilitation after uncemented TKA
Description: patients undergoing an intensive rehabilitation protocol after uncemented tka
Study: NCT05831241

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha
Description: KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
Study: NCT05507021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum DSM 33464, MegaMetalliQ
Description: Pour Lactobacillus Plantarum DSM 33464 sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pour placebo sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
Study: NCT04845659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doptelet Pill
Description: 40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
Study: NCT04845789

Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional. Interview would be conducted for data collection.
Study: NCT05443568

Intervention type: DRUG
Intervention: Oral semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT05674786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Description: Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
Study: NCT06353542

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Software analysis
Description: The tested AI software analyzes the optic disc retinography to determine if the patient is healthy, a glaucoma suspect, or a glaucoma case

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ophthalmologist examination
Description: The ophthalmologist (a glaucoma specialist) will analyze the tests and will examine the patient to determine if the patient is healthy, a glaucoma suspect or a glaucoma case